Literature DB >> 31524767

Does Early Proximal Femoral Varus Osteotomy Shorten the Duration of Fragmentation in Perthes Disease? Lessons From a Prospective Multicenter Cohort.

Wudbhav N Sankar1, Scott M Lavalva1, Molly F Mcguire2, Chanhee Jo2, Jennifer C Laine3, Harry K W Kim2,4.   

Abstract

BACKGROUND: The prognosis of Legg-Calvé-Perthes disease (LCPD) is dependent upon several factors, with the length and severity of the fragmentation stage among the most important. Previous retrospectively collected data from a single center have suggested that early proximal femoral varus osteotomy (PFO) may shorten the length of fragmentation and allow 34% of patients to bypass fragmentation altogether resulting in less femoral head deformity. The purpose of this study was to validate these findings in a prospectively collected multicenter cohort.
METHODS: Patients with LCPD treated with early PFO (during Waldenström stage I) were prospectively followed with serial radiographs at 3-month intervals until a minimum of 2-year follow-up. Waldenström stages and lateral pillar class were determined by mode assessments from 3 pediatric orthopaedic surgeons. The duration of fragmentation was defined as the interval between the first radiographs demonstrating features of stage IIa and stage IIIa. "Complete" bypass was defined as the absence of stage IIa or IIb findings on sequential radiographs with no development of femoral head deformity or collapse. "Partial" bypass was defined as the absence of advanced features of fragmentation and femoral head collapse (stage IIb).
RESULTS: Forty-six patients (80% male individuals) with initial stage LCPD and a mean age of 8.2±1.2 years were identified. The weighted kappa statistics for Waldenström staging and lateral pillar classifications showed excellent (0.833) and substantial (0.707) agreement, respectively. Ninety-eight percent of patients (45/46) underwent some period of fragmentation lasting between 91 and 518 days; the median duration was 206 days (interquartile range, 181 to 280). One patient (2%) bypassed fragmentation completely; 8 patients (17%) demonstrated partial bypass. Patients who completely or partially bypassed fragmentation experienced significantly less severe lateral pillar collapse (P=0.016) and shorter fragmentation duration (P=0.001).
CONCLUSIONS: In this prospective multicenter cohort, we found a lower rate of fragmentation bypass than previously reported. Nonetheless, our data support the previous contention that early PFO may shorten fragmentation and minimize collapse in LCPD compared with historical controls. Further study with larger cohorts and a more rigorous definition of what constitutes bypass is warranted to clarify the effect of early PFO on the reparative biology of LCPD. LEVEL OF EVIDENCE: Level IV-therapeutic study.

Entities:  

Mesh:

Year:  2020        PMID: 31524767     DOI: 10.1097/BPO.0000000000001451

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  4 in total

1.  CORR Insights®: Isolated Trochanteric Descent and Greater Trochanteric Apophyseodesis Are Not Effective in the Treatment of Post-Perthes Deformity.

Authors:  Andrzej Grzegorzewski
Journal:  Clin Orthop Relat Res       Date:  2020-01       Impact factor: 4.755

Review 2.  Evolution of Legg-Calvé-Perthes disease following proximal femoral varus osteotomy performed in the avascular necrosis stage:a prospective study.

Authors:  Kumar Amerendra Singh; Hitesh Shah; Benjamin Joseph; Alexander Aarvold; Harry K W Kim
Journal:  J Child Orthop       Date:  2020-02-01       Impact factor: 1.548

3.  Computer-assisted design model to evaluate the outcome of combined osteotomies in Legg-Calvé-Perthes disease.

Authors:  Hao Li; Zhiqiang Zhang; Changyou Li; Zhenpeng Liang; Zhu Liu; Hai Li; Ziming Zhang
Journal:  Front Pediatr       Date:  2022-08-08       Impact factor: 3.569

Review 4.  [Proximal femoral varus osteotomy in Legg-Calve-Perthes disease].

Authors:  Adam Krátký; Manuel Johannes Kraus; Andreas H Krieg
Journal:  Oper Orthop Traumatol       Date:  2022-08-01       Impact factor: 1.286

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.